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The type I intermediate filament protein keratin 17 has been long implicated as a 
meaningful biomarker for a broad range of carcinomas (Moll et al., 1982), and there is 
emerging evidence that its expression impacts tumorigenesis and related processes. For 
instance, we recently showed that the genetic loss of K17 delays tumor onset in a mouse 
model of basal cell carcinoma, correlating with reduced tumor keratinocyte proliferation and a 
dramatic changes in the immune response in skin, from Th1/Th17- to a Th2-dominated 
cytokine profile (DePianto et al., 2010). There also is evidence that K17 impacts psoriasis, 
where again it would contribute to the dysregulation of the immune response (Fu and Wang, 
2012). These and other studies suggest a link between K17, chronic hyperproliferative and 
inflammatory skin diseases, and the regulation of cytokine gene expression. The molecular 
mechanisms accounting for this intriguing link are not understood. A previously reported 
mass spectrometry-based screen (Chung et al., 2012) identified hnRNP K, an RNA/DNA-
binding protein involved in many aspects of gene expression, as a K17 binding partner. Here 
we show that hnRNP K binds mRNA transcripts encoding the CXCR3 ligands CxCl9, CxCl10, 
and CxCl11, which are involved in pathogenesis of human basal cell carcinomas (Lo et al., 
2010). Furthermore, induction of these genes is both K17- and hnRNP K-dependent, in both 
the A431 human skin cancer line and Gli2tg/+ mouse keratinocytes in primary culture. We also 
show that the expression of the CxCl9, CxCl10, and CxCl11 depends on RSK kinase activity. 
These findings identify a candidate mechanism through which hnRNP K and K17 exert a pro-
tumorigenic influence, the robust stimulation of CXCR3 ligand expression. 
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The metazoan cytoskeleton 
 Before the 1990s, it was mostly accepted that the cytoskeleton is a unique feature of 
eukaryotes, a view that since then has been overturned. Today, bacteria are known to 
posses actin- and tubulin-like proteins (de Boer et al., 1992; Bork et al., 1992) that are 
essential for cell division. This underlines the evolutionary importance of the cytoskeleton for 
reasons beyond a need for structural and mechanical support. Given the acquisition of 
various membrane organelles, eukaryotes needed means of addressing trafficking issues — 
the increased complexity of eukaryotic cells, therefore, was accompanied by a major 
expansion and diversification in cytoskeletal proteins (Wickstead and Gull, 2011). 
Due to a lack of cell wall, metazoa face a significant challenge when it comes to 
providing mechanical support for their cells and tissues. Metazoans generally rely on two 
systems to provide rigidity and support for their tissues. Each cell possesses its own 
cytoskeletal system and cells are connected to one another and their environment in tissues 
using various types of adhesive contacts. The two entities, the cytoskeleton and the adhesion 
apparatus, are often integrated to give rise to integrated supracellular networks. Accordingly, 
the cytoskeleton participates in multiple dynamic processes enabling both mechanical motion 
within the cell and migration of the entire cell (reviewed in Herrmann et al., 2007). 
Metazoan cytoskeletal proteins are commonly classified by the diameter of the 
filaments they form: the 25 nm microtubules, the 10 nm intermediate filaments and the 7 nm 
microfilaments. These filaments are then organized together to form an intricate cytoskeletal 





 Cytoskeletal proteins connect neighboring cells to each other and to the extracellular 
matrix, creating a complex structural multicellular network that is crucially important for 
mechanotransduction (Katsumi et al., 2004; Shafrir and Forgacs, 2002) .  
 Among cytoskeletal proteins, intermediate filament proteins are the most diverse and 





Figure 1. Organization of metazoan cytoskeleton 
Microtubules (MTs), Intermediate filaments (IFs) and Microfilaments (MFs) combine with plakins to form metazoan 
cytoskeletal architecture. Cytoskeletons of neighboring cells are linked via different cell-to-cell junctions as well as 




 Despite their functional diversity, intermediate filament proteins share common 
structural features and can be broadly classified into six different subfamilies (Fig. 2A; Chung 
et al., 2013) based on gene substructure and sequence homology. About 70 different genes 
encoding for intermediate filaments exist in the human genome, with keratins accounting for  
 
54 of these genes partitioned into two sequence types, the type I and type II intermediate 
filament proteins.  
Though the molecular mass of intermediate filament proteins varies substantially 
(from 40 kDa to 240 kDa), they possess a conserved, centrally-located α-helical rod domain 
that is essential for 10 nm filament assembly. The rod domain is flanked by N- and C-terminal 
head and tail domains, respectively, which are highly variable and generally unstructured 
(Fig. 2C). Canonically, the majority of intermediate filament proteins are cytoplasmic, with the 
exception of the nuclear lamins. While cytoplasmic intermediate filaments are known to 
Figure 2. Diversity, structure and polymerization of intermediate filaments 
IFs can be grouped into six groups based on their expression (a). (b) Electron microscopy image showing 10 nm 
keratin filaments. (c) Common structural organization shared by intermediate filament proteins. (a)-(c) from Chung et 




impact nuclear cytoarchitecture (Lee et al., 2012), recent data from our laboratory and others 
indicates that keratins (a class of intermediate filament proteins) can also be found within the 
nucleus (Dr. Ryan Hobbs and Justin Jacob, unpublished data; Kumeta et al., 2013). 
Intermediate filament proteins first assemble to form a dimer, with the two monomers oriented 
in parallel and in register. Dimers then interact along their lateral surfaces with an anti-parallel 
orientation to form structurally apolar tetramers. Tetramers interact through lateral and end-
to-end interactions to give rise to mature 10 nm filaments (see Fig. 2B) that exhibit no known 
structural polarity, a hallmark feature of microtubules (MTs) and microfilaments (MFs). 
Another distinguishing feature of IF proteins is that they do not bind nucleotides (e.g., ATP, 
GTP), which are essential to steady state dynamic properties of F-actin and microtubules. 
Intermediate filaments are implicated in a staggering variety of cellular functions, and, when 
perturbed, are responsible for a myriad of human diseases (see The Human Intermediate 
Filament Database, Szeverenyi et al., 2008). For the purposes of this review, we will focus on 
the keratin gene family. 
 
Keratin gene family 
 Evolutionary, keratins are conserved in higher metazoans and mammals and, in 
humans, are represented by 54 functional genes. Out of these, 17 genes are encoding for 
keratins whose expression is largely restricted to hard epithelia (e.g., hair shaft, nail), while 
the remaining 37 are expressed in soft epithelial tissues.  Keratin genes can be readily 
divided into two IF sequence types based on a phylogenetic approach. The protein products 
of types I and II pair with one another to form obligate heterodimers that polymerize to form 
mature keratin filaments. Type I keratin proteins are acidic in nature and are encoded by 28 
genes in the human genome, while type II keratin proteins are basic to neutral and are 
encoded by the remaining 26 genes (Schweizer et al., 2006). Keratin proteins range from 40 
 
 5 
kDa (type I K19) to 70 kDa (type II K1) in molecular mass: type II basic keratins usually have 
higher molecular mass (40-55 kDa for type I and 56-70 kDa for type II keratins; Moll et al., 
2008).  
 Different pairs of type I and type II keratins are differentially expressed in a tissue- and 
context-dependent fashion (Coulombe and Omary, 2002; Moll et al., 2008; Stoler et al., 
1988), as well as in response to various stimuli (see Fig. 3; Antonini et al., 2013; Karantza, 
2011). 
 
Keratins perform a wide variety of functions in cells, which can broadly be divided into 
mechanical and non-mechanical roles (Kim and Coulombe, 2007; Toivola et al., 2010). The 
importance of keratin filament networks for cell and tissue mechanics is revealed when they 
are mutated in human disease, such as epidermolysis bullosa simplex (EBS) or epidermolytic 
Figure 3. Specificity of keratin expression 
(А) Differential expression of keratins throughout human organs and tissues. (B) Specificity of keratin expression in 
normal human skin layers. Notice, that as epidermal cells differentiate, K5/K14 expression is being phased out, while 
expression is K1/K10 is increasing. CL – cornified layer, GL – granular layer, SL – spinous layer, BL – basal layer, SG 
– sebaceous glands, HS – hair shaft, ORS, IRS – outer and inner root sheath, M – matrix, DP – dermal pappila, IA — 
intradermal apidocytes, PC — panniculus carnosus, a muscle layer supporting the skin. Images are from: (A) 






hyperkeratosis (EHK; see McLean and Moore, 2011 for a review). EBS arises when K5/K14 
filaments are disturbed by mutations in their genes and manifests in extreme tissue fragility 
following exposure to minor mechanical forces, resulting in painful blisters. EHK is a form of 
ichtyosis caused by mutations in either K1 or K10, and presents with general blistering and 
hyperkeratosis. Since K1/K10 are mostly expressed in more differentiated cells of the 
epidermis, blisters in EBS are typically deeper and more painful. A key property of keratin 
filaments that contributes to their importance for cell and tissue mechanics is their connection 
to cell-to-cell and cell-to-matrix adhesive contacts, thereby forming a supracellular network 
contributing to overall tissue rigidity (reviewed in Simpson et al., 2011). Structural studies 
have also pointed out an important role for keratins forming a perinuclear cage that affects 
the size and shape of the nucleus (Lee et al., 2012). Nuclear geometry has been implicated in 
modulating gene expression (Chen et al., 1997).  
 Different keratins (among other IF proteins) are post-translationally modified, which is 
crucial for their participation in signal transduction pathways that allow for non-mechanical 
regulatory functions. Keratins are known to be phosphorylated, ubiquitinated, SUMOylated, 
glycosylated and acetylated at various sites (Snider and Omary, 2014) and these 
modifications contribute, in part, to modulation of their interactions with partner proteins. Non-
mechanical functions of keratins regulate many aspects cell physiology: cell survival and 
death, embryonic development and tissue homeostasis, and cell growth and motility (Fig 4, 
see Chung et al., 2013; Pan et al., 2013 for a review).  
 Accumulating evidence suggests that keratins are actively involved in the modulation 
of immune responses, a phenomenon of special interest to this thesis. A number of keratins 
have demonstrated immunomodulatory properties. In mice, genetic ablation of Krt8 causes 
colitis characterized by an increased Th2 profile associated with an inflammatory response 
(Habtezion et al., 2005). Genetic ablation of Krt1 in mice is associated with an inflammatory 
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skin disease accompanied by the activation of the inflammasome and massive secretion of 
IL-18, a potent proinflammatory cytokine, by K1 null epidermal keratinocytes. Release of IL-
18 was demonstrated to be keratinocyte-autonomous and depletion of IL-18 partially rescued 
the defect (Roth et al., 2012). Keratin 16 was demonstrated to play a role in innate immunity. 
Mice lacking Krt16 exhibit phenotypic features that are clearly related to pachyonychia 
congenita (Lessard and Coulombe, 2012), a human disease that is caused by mutations in 
the KRT16, KRT17 or the KRT6 genes and is characterized by nail dystrophy, palmoplantar 
keratoderma (massive thickening and hyperkeratosis of the palms and soles), along with oral 
and glandular lesions. Additionally, loss of Krt16 in mice induces levels of several damage-
associated molecular pattern genes (DAMPs), which serve as effectors for innate immune 
responses (Lessard et al., 2013). Absence of Keratin 5, a gene responsible for EBS, induces 
classical Th1 markers IL-1b and IL-6 in mouse skin and tissue culture models of EBS (Lu et 
al., 2007). Additionally, ablation of Krt5, but not Krt14 in a mouse model of EBS, induced 
expression of Ccl2, Ccl19 and Ccl20, all of which are nF-kB-dependent genes and involved in 
recruitment of Langerhans cells (a resident dendritic cell in the skin). This finding was in 
agreement with data obtained from skin of EBS patients with K5 mutations, but not K14 (Roth 
et al., 2009). 
Inflammation and immune responses are now widely regarded as drivers of 
tumorigenesis (Couzin-Frankel, 2013). Of special interest to us is Keratin 17 which, as 









Keratin 17: at the crossroads of immunity, inflammation and cancer 
 
Keratin 17, a 46 kDa type I keratin, is often referred to as an inducible keratin. Keratin 
17 expression in normal tissues is largely restricted to ectoderm-derived epithelial 
appendages, including hair follicles, nail beds, sebaceous glands and oral papilla. A great 
mouse model to visualize K17 expression pattern in the skin takes advantage of K17 
promoter to express GFP (Bianchi et al., 2005). In addition, K17 expression can be induced 
by a variety of stimuli, among which are wounding (McGowan and Coulombe, 1998), IFNγ 
(Vogel et al., 1995), EGF (Amit et al., 2007), IL-17A (Shi et al., 2011) and IL-22 (Zhang et al., 
2012),  all of which are typically prominent in the setting of an inflammatory response. 
Figure 4. Non-mechanical functions of keratins 
Different keratins regulate various pathways during development, growth, cell division, survival and homeostasis, cell 
motility and programmed cell death. Keratins accomplish these functions by interacting with a myriad of signaling 
proteins. Frequently, these interactions are mediated by elaborate post-translational modifications of keratins. Image 
from Pan et al., 2013. 
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Mutations in KRT17 cause human diseases, namely pachyonichia congenita type II (McLean 
et al., 1995) and a condition called steatocystoma multiplex (Covello et al., 1998), 
characterized by appearance of sebum-filled cysts in the skin.  
 Psoriasis is an example of a well-studied skin disease setting in which K17 is robustly 
induced (de Jong et al., 1991). Psoriasis is a chronic, inflammatory skin disorder 
characterized by hyperproliferation and aberrant differentiation of keratinocytes (Fu and 
Wang, 2012). While the exact cause of psoriasis is yet to be identified, dysregulation of 
keratinocytes and immune cells are key features of this condition (Lowes et al., 2007). 
Induction of K17 expression occurs very early during the development of psoriatic plaques 
and correlates with an immune shift in skin tissue towards a pro-inflammatory Th1/Th17 
dominated response (Fu and Wang, 2012; Zheng et al., 2007). In addition, K17 peptides 
containing ALEEAN sequence may serve as an autoimmune epitope in psoriasis, promoting 
proliferation of T-lymphocytes and exaggerating the condition (Shen et al., 2005; see 
Gudmundsdottir et al., 1999). In light of these findings, K17 has been suggested as a 
potential candidate target for psoriasis therapy (Fu and Wang, 2012). In addition to having an 
emerging role in the pathogenesis of psoriasis, multiple lines of evidence link K17 to various 
cancers (Markey et al., 1992; Moll et al., 1982). Indeed, K17 is expressed in basal cell 
carcinoma (Markey et al., 1992), breast (Nielsen et al., 2004), cervical (Smedts et al., 1992), 
lung (Chen et al., 2011), pancreatic (Sarbia et al., 2007; Yang et al., 2012), gastric (Ide et al., 
2012) and ovarian (Wang et al., 2013) cancer. K17 expression often correlates with poorer 




 Despite a significant amount of information about K17 as a marker for various 
cancers, the exact molecular function of K17 expression in these settings is yet to be defined. 
A number of studies have examined K17’s roles in signaling cascades. K17 was found to 
control hair follicle cycling in a TNFα-dependent fashion (Tong and Coulombe, 2006), which 
is an interesting connection to a pro-apoptotic TNFα pathway. Another defined role of K17 is 
to regulate protein synthesis and cell growth. Phosphorylated K17 is able to interact with 14-
3-3σ, increasing cytoplasmic presence of this adaptor protein and leading to activation of the 
Akt/mTOR pathway, protein synthesis, and epithelial cell growth (Kim et al., 2006; Sankar et 
al., 2013). This set of findings is especially exciting in light of emerging data regarding the 
differential regulation of T-helper lymphocyte responses by mTORC1 and mTORC2 
Figure 5. K17 expression in tumors correlates with poorer patient prognosis 
In case of epithelial ovarian cancer (A), cancerous tissues express significantly more K17 (A, left panel), which correlated with 
decreased survival rate after operation (A, right panel; Wang et al., 2013). In case of gastric adenocarcinoma (B), K17-
expressing tumors tend to be more aggressive, which is reflected by decreased both overall survival time (B, left panel), and is 
even more apparent if tumor was found in the antrum region (B, right panel; Ide et al. 2012) 
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complexes (Delgoffe et al., 2011). K17 expression correlates with polarization of immune 
responses in psoriasis (see above) and additional evidence comes from a recent study by 
DePianto et. al. (2010). In this latter study, the impact of genetically ablating Krt17 was 
examined in a mouse model of basal cell carcinoma, driven by sustained expression of a Gli2 
transgene (Gli2tg/+ ) in the skin. In this setting, the absence of K17 not only delayed tumor 
onset (Fig. 6), but also polarized immune profile from a Th1/Th17 to a Th2-dominated profile. 
The observed effect was K17-specific and did not occur when the Krt14 gene was similarly 





 The study by DePianto et al. thus provided important clues about a possible molecular 
mechanism by which K17 may exhibit tumor-promoting properties and laid a solid foundation 
for deeper investigation of this phenomenon. To address this, a mass spectrometry-based 
screen for K17-binding proteins was conducted in our laboratory (Chung et al., 2012). 
Analysis of such K17-associated partners identified heterogenous nuclear ribonucleoprotein 
K (hnRNP K), a member of hnRNP family of proteins that are involved in various processes 
a
Figure 6. Absence of K17 delays tumor onset in mouse model of basal cell carcinoma. 
(a) Gli2tg mice spontaneously develop BCC-like tumors on their ears, and tumor onset is delayed when K17 null mice are used. 
Left panel shows a typical ear lesion at P80. Right panel shows dramatic thickening of the epithelium in the BCC-like tumor. 
Epithelial thickness is reduced when K17 is absent. (b) and (c) quantification of onset delay (b) and percentage of mice with 
tumors at P80 (c) caused by absence of K17. Image from DePianto et al., 2010. 
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related to gene expression (Han et al., 2010). The K17-hnRNP K interaction was further 
confirmed by reciprocal endogenous coimmunoprecipitation assays (Dr. Byung Min Chung, 
unpublished data), thus paving the way for an investigation of the functional significance of 
this interaction. 
 
hnRNP K and tumorigenesis 
 hnRNPs are a family of multifunctional proteins with a central role in the regulation of 
mRNA maturation, splicing, DNA damage repair, telomere maintenance and other functions 
(Chaudhury et al., 2010; Makeyev and Liebhaber, 2002). hnRNPs can post-transcriptionally 
regulate expression of mRNAs by binding to 3’-UTR regions (Swanson and Dreyfuss, 1988) 
and participate in the regulation of RNA stability. hnRNPs are organized in RNP particles — 
multimolecular protein/RNA complexes of variable composition that are thought to be 
nucleated by hnRNP C (König et al., 2010) protein. There is a subset of hnRNP proteins,  
termed poly(C)-binding proteins, that show a preference for binding to poly(C)-rich sequences 
on RNAs (PCBPs; Dreyfuss et al., 1993). The 51 kDa hnRNP K protein is a member of this 
subset (Matunis et al., 1992). 
 The amino acid sequence of hnRNP K shows three distinct “K domains” discovered to 
represent a common RNA-binding motif, now defined as “K-homology (KH) domains” 
(reviewed in Valverde et al., 2008). The hnRNP K protein also possesses a nuclear 
localization signal (NLS; Michael et al., 1997) and, therefore, is predominantly nuclear in 
normal tissues. This said, it has been observed in the cytoplasm, in mitochondria, and in the 
vicinity of the plasma membrane (Mikula et al., 2006). hnRNP K is also known to be 
phosphorylated by various kinases that affect its function (Habelhah et al., 2001a; Ostareck-
Lederer et al., 2002; Sataranatarajan et al., 2008). For example, hnRNP K phosphorylation by 
ERK promotes its cytoplasmic accumulation and has been associated with inhibition of 
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translation of hnRNP K-dependent mRNAs (Habelhah et al., 2001b). hnRNP K can also 
participate in signaling cascades by recruiting ERK components directly to sites of 
transcription (Mikula and Bomsztyk, 2011) 
 hnRNP K is a particularly interesting ribonucleoprotein, in part due to the breadth of its 
interactome. hnRNP K interacts with a staggering number of proteins that perform a wide 
array of cellular functions (Mikula et al., 2006) and same can be said for the known RNA 






hnRNP K has already been implicated in inflammation and cancer progression. For 
instance, the importance of hnRNP K in inflammation is manifested through its ability to 
control the stability of COX2 mRNA (Shanmugam et al., 2008), which encodes an enzyme 
crucial for synthesis of prostaglandins. The clinical importance of COX2 in inflammation has 
made this enzyme one the most common targets of non-steroidal anti-inflammatory drugs 
C
BA
Figure 7. hnRNP K interactome 
(A) Protein interactome of hnRNP K revealed interaction with proteins participating in various functions, the most common  
being RNA/nucleic acid/ATP binding. Mikula et al., 2006.  hnRNP K-bound RNAs participate in many cellular functions as well 
(B) and are localized to various sites within the cell (C). Liu and Szaro, 2011. 
 
 14 
(NSAIDs). In the cancer setting, hnRNP K is known to be overexpressed, enhancing cellular 
proliferation and transformation (Barboro et al., 2009; Carpenter et al., 2006; Gao et al., 2013; 
Mandal et al., 2001; Roychoudhury and Chaudhuri, 2007) and, interestingly, the subcellular 
localization of hnRNP K becomes more cytoplasmic in tumors (Chen et al., 2009; Inoue et al., 
2007). Given that our laboratory has discovered that the cytoplasmic localization of hnRNP K 
depends in part on K17 protein (Dr. Byung Min Chung, unpublished data), we reasoned that 
the impact of K17 on BCC tumor progression could be mediated, at least partly, by interaction 
with hnRNP K.  
We hypothesized that K17 exhibits immunomodulatory effects on cytokine expression 
through its interaction with hnRNP K, identified by Dr. Byung Min Chung. Therefore, we 
decided to test association of hnRNP K with K17-dependent targets (using the RIP assay) 
encoding for these cytokines and investigate their dependence on hnRNP K by modulating 
















hnRNP K protein binds several mRNAs coding for potent cytokines 
 To better understand the role of hnRNP K in K17-mediated regulation of immune profile 
of cytokine expression, we first performed hnRNP K RNA immunoprecipitation (RIP) assays, 
which involves precipitation of target RNA-binding protein and subsequent isolation of bound 
RNAs. The procedure was performed using lysates obtained from both A431 human 
epidermoid carcinoma cells, which are known to express K17 among other keratins (Moll et 
al., 1982), and Glitg/+ mouse epidermal keratinocytes in primary culture. Isolated RNA from 
hnRNP K precipitates and negative control IgG was analyzed by qRT-PCR using target-
specific primer pairs (see Materials and Methods). Consistently with published data, the 
mRNA transcripts coding for MYC (Evans et al., 2003),  PTGS2 (Shanmugam et al., 2008) 
and EGR1 (Mikula and Bomsztyk, 2011) are highly enriched in hnRNP K RIPs in both types 
of cell lysates, relative to negative control IP (Fig 8). mRNAs coding for various chemokines 
and cytokines, including IL4, IL17C, AIRE  and TSLP, are also selectively enriched in hnRNP 
K precipitates. An interesting observation is that the KRT17 transcript also precipitates 
effectively in the hnRNP K RIP assay, raising the prospect that K17 expression might be by 
hnRNP K at the transcriptional or posttranscriptional level. Of special interest to us are the 
mRNAs encoding CXCL9, CXCL10 and CXCL11, the protein products of which are ligands 
for the CXCR3 receptor.  These ligands (and their cognate receptor) function to regulate 
immune cell trafficking during Th1 immune responses, which is promoted by K17 in the Gli2tg 
mouse model of basal cell carcinoma (DePianto et al., 2010). The CXCR3 axis has well 
established functions during tumor development in various models (Kawada et al., 2007; Lo 
et al., 2010; Ma et al., 2009; Wu et al., 2012). Expression of the CXCL9, CXCL10 and 
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CXCL11 genes was found to be robustly K17-dependent, in three different experimental 
paradigms exploited in our laboratory:the  HPVtg mouse, the Glitg/+ mouse and human A431 
cells treated with 12-O-tetradecanoylphorbol-13-acetate (TPA; Dr. Ryan Hobbs, unpublished 
data), a phorbol ester which induces contact dermatitis (Hickey et al., 1981) with expression 
of various cytokines via the NF-kB pathway (Catley et al., 2004). 
 To test whether the association of hnRNP K with CXCL9, CXCL10 and CXCL11 
mRNAs requires K17, we performed RIP assays using A431 cells stably expressing either a 
KRT17-directed  shRNA or a scrambled control (see Chung et al., JBC 2012). Cells were 
 
Figure 8. hnRNP K RNA immunoprecipitation assays. 
hnRNP K RIP assays were performed using primary keratinocytes from newborn Gli2tg Krt17+/-  mice (A) or A431 cells 
(B) and analyzed by qRT-PCR. Data is normalized to IgG control. Insets demonstrate successful hnRNP K 
immunoprecipitation relative to normal IgG negative control as shown by anti-hnRNPK immunoblotting of precipitates. 





serum-starved prior to stimulation with TPA (or DMSO vehicle control) and RIP was 














































































Figure 9. K17 enhances association of hnRNP K with selected transcripts 
hnRNP K RIP assays were performed using primary keratinocytes from newborn Glit/+g Krt17-/-  mice. Data normalized 
to IgG control. (A) or A431 cells treated with TPA or DMSO vehicle control (C), and analyzed by qRT-PCR. For (C), 
data was normalized to DMSO-treated hnRNP K samples and inputs. In (B), anti-hnRNP K and anti-K17 antibodies 
were used to analyze immune precipitates (IP) or the input sample (Input) by immunoblotting. Where present, error 
bars indicate SEM. A log scale used for the Y-axis in (A). 
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 LIkewise, complete absence of K17 (genetic null, Fig. 9 A) reduces association of 
hnRNP K with target transcripts in Glitg/+ mouse epidermal keratinocytes in primary culture, 
with the most dramatic decreases observed for CXCL11 and EGFR transcripts. In contrast, 
association of hnRNP K with its previously known targets (PTGS2, MYC, EGR1) does not 
seem to be affected by the K17 status. The latter experiment needs to be repeated to ensure 
full reproducibility. When RIP is carried out using serum starved A431 cells treated with TPA 
or DMSO, a stronger association between hnRNP K protein and the CXCL9, CXCL10 and 
CXCL11 transcripts occurs upon TPA treatment in cells stably expressing scrambled shRNA 
compared to cells expressing KRT17 shRNA. These findings establish hnRNP K protein as a 
binding partner and a potential regulator for a significant number of cytokine mRNAs, in a 
K17-dependent fashion, and also strongly suggests hnRNP K’s involvement in CXCR3 
signaling cascade, which has important implications for carcinogenesis. 
 
CXCL9, CXCL10 and CXCL11 transcripts are hnRNP K-dependent 
 To examine the role of hnRNP K in the regulation of the CXCL9, CXCL10 and 
CXCL11 transcripts, we carried out siRNA-mediated knockdown of hnRNP K in A431 cells, 
and assessed whether TPA-induced upregulation of these mRNAs occurs normally. All three 
hnRNP K siRNAs tested, designed to target different regions of HNRNPK, demonstrated high 
knockdown efficiency (96%, 83% and 91%, for siRNA1, siRNA2 and siRNA3 at the mRNA 
level, respectively; see Fig 10 A). siRNA1 was used in all subsequent experiments. As 
expected, compared to non-silencing (NS) control siRNA, hnRNP K knockdown A431 cells 
showed a dramatic decrease in their ability to induce cytokine mRNAs (namely CXCL9, 
CXCL10 and CXCL11) following TPA treatment (Fig 10 B). The CXCR3 mRNA does not 
behave in the same way, nor does IL4, which is an important Th2 marker, supporting the 
importance and specificity of hnRNP K-K17 interaction in promoting a Th1, rather than a Th2, 
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response. An interesting observation is that the KRT17 mRNA behaves similarly to CXCL9, 
CXCL10 and CXCL11, which is in agreement with the hnRNP K RIP results whereby the 
KRT17 transcript is robustly enriched compared to negative control. The full significance of 
the latter finding remains to be established, through additional experimentation. Taken 
together with the RIP-based results, the outcome of these experiments indicates that not only 
does hnRNP K bind to CXCL9, CXCL10 and CXCL11, but also regulates their expression, at 
least in the TPA paradigm. 
 
Figure 10. hnRNP K siRNA knockdown in cultured A431 tumor keratinocytes. 
hnRNP K was knocked down using siRNAs targeting different regions of HNRNPK (A), all of which demonstrated 
great efficiency in decreasing steady state HNRNPK levels, with siRNA 1 being the most effective. (B) A431 cells 
transfected with non-silencing (NS) or hnRNP K siRNA1 were serum starved and treated with TPA. RNA was isolated 






























































hnRNP K cooperates with K17 to regulate expression of CXCR3 ligands 
 To test whether hnRNP K depends on K17 to mediate CXCR3 ligands expression, 
we next overexpressed mCherryC1-hnRNPK in A431 cells. Transfecting A431 cells is known 
to be challenging, with high cytotoxicity being an issue, and we therefore decided to first test 
a variety of transfection reagents (Lipofectamine3000, FugeneHD, Fugene6, GeneJuice, 
Xfect, Continuum, and TransIT) with the mCherryC1-vector (Fig 11 A). Gross cell 
morphology, along with upregulation of target genes in response to TPA, served as 
complementary reporters for relative cytotoxicity. All the reagents tested decreased the 
responsiveness of A431 cells to TPA. FugeneHD (FuHD) was selected for our studies based 
on its combination of relatively low toxicity and acceptable retention of TPA responsiveness. 
Next, mCherryC1 Vector control or mCherryC1-hnRNPK were overexpressed in A431 cells to 
test whether hnRNP K overexpression increases the response to TPA stimulation, relative to 
vector control (Fig. 11 B). hnRNP K was successfully overexpressed as evident from (Fig. 11 
D, left), and cells expressing hnRNP K were indeed found to be more responsive to TPA-
induced upregulation of CXCR3 ligands (Fig. 11 B). As with the hnRNP K knockdown, mRNA 
levels for the Th2 marker IL4 were not affected in this experiment (Fig. 11 B). To investigate 
whether K17 plays a role in hnRNP K’s effects on CXCR3 ligand transcript levels, we next 
overexpressed hnRNP K in either KRT17 shRNA-expressing A431 cells or A431 cells 
expressing control shRNA (Fig11 C; for degree of overexpression is demonstrated in Fig. 11 
D, right). A431 cells expressing control shRNA exhibited higher TPA responsiveness upon 
hnRNP K overexpression compared to cells expressing KRT17 shRNA, as showed by higher 
relative levels of CXCL9, CXCL10 and CXCL11 mRNAs. Such a cooperation between 
hnRNP K and K17 is especially interesting in light of recent findings, from in our laboratory, 
showing that K17 affects the subcellular localization of hnRNP K (Dr. Byung Min Chung, 
unpublished data), together with the observation that presence of hnRNP K in the cytoplasm 
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is important in carcinogenesis (Lundberg et al., 2010; Uhlén et al., 2005; Zhou et al., 2010). 
Additionally, K17 was recently found to occur within the nucleus (Dr. Ryan Hobbs, 
Figure 11. hnRNP K regulates CXCR3 ligands expression in K17-dependent fashion 
(A) Comparison of different transfection reagents to assess their effects on the response of A431 cells to TPA 
treatment. (B,C) mCherryC1-hnRNP K was overexpressed in A431 cells (B) or A431 cells stably expressing 
KRT17 shRNA or scrambled control (C). Cells were serum starved and treated with TPA, and RNA was 
isolated and subjected to qRT-PCR analysis. Frame (D) shows efficiency of hnRNP K overexpression using 

























































unpublished data), opening exciting possibilities for a broad and far ranging relationship 
between hnRNP K and K17, and dynamics of this interaction in response to various stimuli. 
Taken together, these findings establish that expression of CXCR3 ligands is both hnRNP K- 
and K17-dependent. 
 
K17 impacts the stability of CXCR3 ligand mRNAs  
 hnRNP K participates in formation of various RNP complexes that have defined 
roles in RNA metabolism such as splicing and RNA degradation (Bomsztyk et al., 2004). To 
test whether K17 exhibits any effect on RNA stability (that can be possibly mediated by K17-
hnRNP K interaction), we carried out an “actinomycin D pulse chase experiment”. 
Actinomycin D is a potent transcription inhibitor and allows for the monitoring of mRNA decay 
over time. To test for the stability of CXCR3 ligand mRNAs, SCR shRNA- or KRT17 shRNA-
expressing A431 cells were serum-starved and pretreated with DMSO or TPA for 1.5 hours to 
induce transcription of CXCR3 ligands. After TPA treatment, cells were incubated with 
actinomycin D or DMSO control for 4 hours. We found that the CXCL9, CXCL10 and CXCL11 
mRNA levels are similar between actinomycin D- and DMSO-treated cells, indicating that 
these transcripts are relatively stable in cells when K17 levels are normal, at the 4 hours time 
point (Fig. 12). However, cells expressing KRT17 shRNA showed decreased levels of 
CXCL11 mRNA in actinomycin D-treated cells compared to those treated with DMSO, with a 
weaker impact on CXCL9 and CXCL10 mRNAs. This experimental outcome suggests that 
the effects of K17 on the levels of CXCR3 ligand mRNAs are, at least partly, due to a 
















RSK is involved in regulating the expression of CXCR3 ligands 
 
 Both K17 and hnRNP K are phosphorylated by various kinases. hnRNP K is 
modified by c-Src, JNK, PKC and Erk kinases (Habelhah et al., 2001a; Ostareck-Lederer et 
al., 2002; Sataranatarajan et al., 2008) and physically interacts with RSK (Kanlaya et al., 
2010), while K17 is known to be phosphorylated by RSK kinase (Pan et al., 2011). With so 
many different kinases possibly involved in regulation of the K17-hnRNP K interaction, all of 
which are potent mediators of signal transduction pathways, we decided to use a panel of 
specific inhibitors to see if inhibition of any kinase will show a pronounced effect on induction 
of CXCR3 ligand expression (Fig. 13 A).  
 RSK inhibition led to the strongest attenuation of the response of A431 tumor 
keratinocytes to TPA. p38 inhibition also decreased CXCR3 ligands induction. PKA and PKC 
inhibitors exhibited little effect, while, interestingly, MEK and ERK inhibition resulted in 
increased TPA responsiveness due to considerably lowered steady state levels of CXCR3 
ligand mRNAs. We decided to focus our subsequent efforts on RSK and performed siRNA-
mediated knockdown of RSK in A431 cells to test whether the outcome observed will mimic 
the effect of inhibiting the enzyme.  
Figure 12. Use of Actinomycin D to test the stability of specific mRNAs. 
Serum starved A431 cells expressing scrambled (SCR) or KRT17 shRNA were initially treated with TPA and 
subsequently with actinomycin D for 4 hours. RNA was isolated from cells and analyzed by qRT-PCR. Bars indicate 




 As expected, the outcome of a RSK knockdown closely resembled that of RSK 
inhibition, strongly attenuating CXCR3 ligands induction upon TPA stimulation (Fig. 14). 
Decrease in TPA response seems to be more pronounced with lower levels of K17 in KRT17 
shRNA expressing cells. More experiments are necessary, however, to establish statistical 
significance. This data strongly suggests that RSK activity is necessary for induction of 
CXCR3 ligands. 
 

















 Figure 13. Kinase inhibition suggests that RSK involvement in regulating CXCR3 ligands 
(A) A431 cells were pre-treated with various kinase inhibitors or DMSO control and subsequently 
stimulated with TPA (+TPA) or DMSO (-TPA). RNA was harvested and analyzed by qRT-PCR. X axis 
labels indicate names of inhibitors and their target kinases. Data is normalized to DMSO. (B) 
Pretreatment of A431 cells with BI-D1870, a potent RSK inhibitor, followed by TPA treatment and qRT-
PCR analysis revealed that RSK activity is necessary for proper induction of CXCR3 ligands mRNAs, but 
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Different stimuli exhibit different degrees of K17-dependence   
  In addition to TPA, which induces CXCR3 expression in a K17-dependent fashion 
(Fig. 15 A), we decided to test additional stimuli to induce CXCR3 ligands. SCR or KRK17 
shRNA expressing A431 cells were treated with EGF or IFNγ, which are known inducers of 
K17 expression. Both treatments robustly induced CXCR3 ligands expression, however, 
these responses did not exhibit K17 dependence, as in the case for TPA (Fig 15). Since 
some degree of K17-dependence was observed at lower concentrations of IFNγ, more 
experiments are needed to fully understand response to these stimuli with regards to K17 
status. 
 These findings underline that K17’s contribution in regulating the immune response 
in vivo is likely to be very specific. Even more importantly, with many cell types and signaling 
cascades involved in establishment of Th1 adaptive response, interplay and balance between 
K17-dependent and K17-independent responses becomes complicated and needs to be 
examined carefully. 
 Together, these results suggest existence of a K17-hnRNP K-CXCR3 axis, that is 
likely important for the observed effects of K17 on tumorigenesis in vivo.  
 
 
Figure 14. RSK siRNA-mediated knockdown 
SCR shRNA or KRT17 shRNA-expressing A431 cells were transfected with NS or RSK siRNA and 



















































































































































































Figure 15. Treatment with different stimuli 
SCR shRNA or KRT17 shRNA-expressing (17C) A431 cells were serum starved and treated with TPA (A) or   (B) EGF 






Proper appreciation of the findings reported in this thesis call for the consideration in 
the broader setting of the hnRNP K project in the Coulombe laboratory and, in particular, the 
substantive data set generated by Dr. Byung Min Chung. In Dr. Chungs’ experiments, K17 
was found to be important for cell transformation in an anchorage-independent cell growth 
assay, as well as cell invasion in a Matrigel invasion assay. These effects were found to be 
mediated by CXCR3 signaling, and elevated levels of CXCL11 and CXCL9 proteins were 
observed by ELISA in the growth medium containing cells with normal K17 level compared to 
cells expressing K17 shRNA. Further, using anti-CXCR3 antibody or a chemical antagonist 
successfully prevents K17-dependent cell transformation as assessed in the anchorage-
independent growth assay.  Therefore, cells expressing normal levels of K17 are secreting 
pro-inflammatory molecules that are responsible for the observed pro-inflammatory properties 
of K17 in vivo. Indeed, substantially more immune cells infiltrate the tumorigenic ear lesions 
occurring in Krt17+/+;Gli2tg/+ than in Krt17-/-;Gli2tg/+ animals (DePianto et al., 2010). hnRNP K 
was also found to be implicated in this process: siRNA-mediated knockdown of hnRNP K 
decreases the number of transformed colonies in anchorage-independent growth assay 
along with lowers levels of CXCL11 in the serum. The cytoplasmic level of hnRNP K was also 
decreased in ear lesions of Krt17-/-;Gli2tg/+ mice compared to those in Krt17+/+;Gli2tg/+ mice 
(Dr. Byung Min Chung, unpublished data), thus supporting the involvement of hnRNP K in 
K17-dependent tumorigenesis. However, more studies are required to define the exact role of 
hnRNP K in Gli2tg/+ mice. Therefore, multiple lines of evidence suggest that K17 and hnRNP 
K partner up to regulate inflammation and tumorigenesis via, at least partially, CXCR3 
pathway. This is especially intriguing considering that each of the key players identified in 
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these experiments has been individually implicated in the carcinogenesis and inflammation in 
various models. The novelty of these observations resides in the fact that K17, hnRNP K and 
CXCR3 signaling are found to work closely together to contribute to the observed phenotype. 
Furthermore, this study highlights importance of RSK, another prominent player in cancer 
development (Anjum and Blenis, 2008; Sulzmaier and Ramos, 2013), in regulating effect of 
the K17-hnRNP K interaction and its downstream effects.  
A number of questions follow from this body of work and need to be addressed in the 
future to foster a better understanding of the emerging K17-hnRNPK-CXCR3 signaling axis, 
some of which will be discussed here, especially in light of recent findings in our laboratory. 
A pressing issue is to define the binding interface between hnRNP K and K17. 
Understanding which regions of the K17 and hnRNP K proteins are particularly important for 
their interaction may provide useful tools to further understand the physiological significance 
of this interaction, and a promising target for intervention that may be of clinical benefit. To 
address this issue hnRNP K truncation mutants, or, on K17’s side, various K17-K14 chimeras 
can be useful to investigate importance of various segments in each participating protein. 
Investigating the role of the posttranslational modifications known to occur on both proteins in 
regulating the K17-hnRNP K interaction also represents an interesting direction for future 
research.  
From hnRNP K perspective, it might be of value finding out which region of the protein 
mediates K17-dependent effects on gene expression. hnRNP K may preferentially use any of 
its three KH domains for regulating K17-dependent target RNAs. Utilizing a non-biased 
analysis of hnRNP K RIPs, such as RIP-Seq, CLIP (crosslinking and immunoprecipitation) or 
iCLIP (individual-nucleotide resolution CLIP) (König et al., 2010), may help identify additional 
targets of hnRNP K that may also be K17-dependent. An additional benefit of using CLIP or 
iCLIP is the ability to identify hnRNP K-binding sites on the target bound RNAs.   
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While keratins are not known to bind DNA directly, our laboratory has observed the 
occurrence of K17 within the nucleus (Dr. Ryan Hobbs and Justin Jacob, unpublished data). 
Chromatin immunoprecipitation (CHIP) assays using anti-K17 antibody revealed an 
enrichment for select promoter sequences, among which are promoters for CXCR3 ligand-
encoding genes. While this approach does not answer whether or not K17 itself directly binds 
DNA or this interaction occurs via another protein, an attractive (and conservative) possibility 
is the physical and functional involvement of K17 in a multi-protein complex in the nucleus. 
We are planning to examine this and related scenarios through the use of electrophoretic 
mobility shift assays (EMSAs) using antibodies for specific proteins of interest, and probes 
corresponding to relevant promoter sequences. A protein of particular interest is Autoimmune 
Regulator (AIRE), a transcriptional regulator that also interacts with K17 protein, both 
physically and functionally. The AIRE transcript is enriched in hnRNP K RIPs (this thesis), is 
expressed in mouse skin, and overexpression of AIRE protein restores the inability of K17 
shRNA-expressing A431 cells to induce cytokines upon TPA stimulus (Dr. Ryan Hobbs, 
unpublished data). Given the hnRNP K RIP data, AIRE likely lies downstream of the K17-
hnRNP K interaction. The impact of AIRE on the K17-hnRNP K interaction, and the 
associated downstream effects, are certainly of great interest but remains to be elucidated. 
 Another significant issue left unaddressed is discerning between a mode of action at 
the transcriptional vs. posttranscriptional effects for the K17-hnRNP K protein complex. 
Considering K17’s presence in the nucleus, K17 may be regulating gene expression at both 
steps: for instance, from providing a scaffold for transcriptional regulatory complexes in the 
nucleus to influencing RNA stability through hnRNP K in the cytoplasm (the latter has been 
observed in this study; see Fig. 12). hnRNP K itself may also function at both the 
transcriptional and posttranscriptional levels —this remarkable protein is for instance known 
to be a part of the basal transcriptional machinery via interaction with TATA-binding protein 
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(TBP; Michelotti et al., 1996) and also regulate various aspects of RNA metabolism by 
binding target RNAs. Canonical hnRNP K-controlled transcripts (EGR1, MYC, PTGS2) all 
possess a poly-(C) motif, which are not readily obvious in the CXCR3 ligands mRNAs. 
Therefore, it is important to elucidate the hnRNP K binding sites on these mRNAs, and this 
may give additional clues as to how hnRNP K controls these transcripts as well as provide 
basis for a sequence homology search of other hnRNP K-regulated transcripts. 
 Another interesting observation is whether hnRNP K can regulate K17 itself. The 
KRT17 transcript is robustly enriched in hnRNP K RIPs, and when hnRNP K siRNA is used, 
the expected increase in K17 expression following TPA treatment (as measured by RNA 
levels, and of a modest nature) does not occur as it does in control cells. At this point, this 
data remains inconclusive and more experiments need to be performed.  
 Combining the experiments reported in this thesis with those performed by Dr. Byung 
Min Chung lead us to propose a model whereby the RSK kinas-regulated interaction between 
K17 and hnRNP K interaction controls the expression of CXC3 ligand, as well as CXCR3-
dependent signaling, in the setting of tumorigenesis. These finding are the first mechanistic 











Materials and methods 
 
Mouse models 
C57BL/6 Krt17-/- mice were crossed to C57BL/6 Gli2tg/+ transgenic mice to create 
Krt17-/-; Gli2tg/+ mice, and relevant controls, as described (DePianto et al. 2010). Genotyping 




Human A431 cell lines (ATCC) stably expressing K17 shRNA or K17 scrambled RNA  
(Chung et al., 2012) were grown in 1g/L DMEM medium with glutamine (Gibco) 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin mixture (Gibco) 
and puromycin (Sigma). Cells were grown at 37°C with 5% CO2. Subconfluent cultures were 
split by trypsinization (0.05% Trypsin-EDTA, Gibco), with trypsin deactivation by addition of 
10% FBS DMEM. Cells were pelleted by centrifugation for 5 minutes at 4°C and 350 g. 
Pellets were resuspended in 10% FBS DMEM and plated on 10 or 20 cm dishes or 6-well 
plates (Corning). Primary cultures of skin keratinocytes from 2-day-old mouse pups of age-
matched or littermate Krt17-/-;Gli2tg/+ and Krt17+/+;Gli2tg/+ mice were isolated as described 
(Bernot et al., 2004) and maintained in Cnt-57 media (CELLnTEC). 
 
hnRNP K Overexpression 
 A431 cells were grown on 6-well plates until 50-60% confluent, and medium was 
changed to fresh 10% FBS DMEM. The HNRNPK cDNA was cloned out of pCMV6-AC 
hnRNP K (Origene) using PCR, with oligonucleotide primers (forward) 5′-
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TCGAATTCTGATGGAAACTGAACAGCCAGAAG-3′ (EcoRI restriction site underlined) and 
5′-ATCCCGGGCTTAGAATCCTTCAACATCTGCAT AC-3′ (reverse) (XmaI restriction site 
underlined) and cloned into mCherry-C1 (Clontech). 1.5 µg of plasmid DNA (pmCherry C-1 
vector encoding mCherry-hnRNP K or vector control encoding mCherry) was transfected into 
each well by mixing it with Fugene HD reagent (Promega) using 3:1 ratio (3 µL of Fugene HD 
to 1 µg of DNA) in 200 µl of serum-free medium (OPTI-MEM, Gibco). Following 15 min 
incubation at RT, suspension was added to the cells dropwise. Next day, the medium was 
changed, and cells were lysed to harvest RNA at 48 hrs after transfection. Overexpression of 
HNRNPK was confirmed by qRT-PCR or Western blotting. 
 
hnRNP K or RSK knockdown by RNA interference 
 A431 cells were grown on 6-well plates until 50-60% confluent, and medium was 
changed to fresh 10% FBS DMEM. hnRNP K knockdown was performed using designed 
duplex siRNA or scrambled siRNA as a control. The sequences used are as follow:  
hnRNP K siRNA:   5’-CCUAUGAAGCAGAGGAAUGUUGGCUUU-3’ 
                 5’-AGCCAACAUUCCUCUGCUUCAUAGG-3’ 
scrambled siRNA: 5’-GUCUAACAGCCGUUACACACCUUAGAU-3’ 
                 5’-CUAAGGUGUGUAACGGCUGUUAGAC-3’ 
 “On target plus SMARTpool RSK1 siRNAs” from Dharmacon were previously 
described in a published report from our laboratory (Pan et al. 2011). 7µl of 10 µM Duplex 
RNA was mixed with 7µl Lipofectamine RNAiMAX (Invitrogen) in serum-free media (OPTI-
MEM, Gibco). Following 5 min incubation at RT, suspension was added to the growing cells 
in wells of a 6-well plate dropwise. RNA was harvested after 48 hrs after transfection. 





 Growing cells were washed twice with nuclease-free PBS (Ambion). RNA was 
isolated from cells using Clontech NucleoSpin RNA kit according to manufacturer’s protocol. 
Concentration and purity of RNA samples (A260/230 and A260/280 ratios) was measured by 
spectrophotometry (IMPLEN P330 spectrophotometer). 
 
cDNA synthesis and qRT-PCR 
 1 µg of RNA was reverse transcribed using iScript cDNA synthesis kit (Bio-Rad) 
according to manufacturer’s instructions. 
 qRT-PCR was performed on 50 ng of cDNA per well (Hard Shell 96 well PCR plates, 
Bio-Rad) using iTaq Universal SYBR Green Supermix (Bio-Rad) on C1000 Thermal Cycler 
(Bio-Rad) with CFX96 Real-Time system (Bio-Rad) using following reaction protocol: 
1. 95°C for 5 min 
2. 40 cycles of amplification (95°C for 10 sec; 60°C for 30 sec; repeat) 
3. 95°C for 10 sec 
4. Melting curve was plotted for 65°C-95°C in 0.5°C increments for 5 sec. 
Amplification curves were visualized by CFX Manager 3.1 software (Bio-Rad). Relative fold 
changes were calculated using the 2-ΔΔCq method, normalizing to RPS18 and Actin levels. 
Percent input method was used to calculate fold enrichment as compared to the negative IgG 
control for RIP assays. 
Target-specific primer pairs were synthesized by IDT and were as follows: 
Gene Direction Primer sequence 5'- 3' 
KRT17 Forward GGTGGGTGGTGAGATCAATGT  
Reverse CGCGGTTCAGTTCCTCTGTC  
AIRE Forward CCAGGCTCTCAACTGAAGGC  
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Reverse GAATCCCGTTCCCGAGTGG  
CXCL9 Forward GTAGTGAGAAAGGGTCGCTGT  
Reverse AGGGCTTGGGGCAAATTGTT  
CXCL10 Forward GTGGCATTCAAGGAGTACCTC  
Reverse TGATGGCCTTCGATTCTGGATT  
CXCL11 Forward GACGCTGTCTTTGCATAGGC  
Reverse GGATTTAGGCATCGTTGTCCTTT  
CXCR3 Forward CCACCTAGCTGTAGCAGACAC 
Reverse AGGGCTCCTGCGTAGAAGTT 
IL17A Forward TCCCACGAAATCCAGGATGC   
Reverse TGTTCAGGTTGACCATCACAGT 
IL6 Forward AATTCGGTACATCCTCGACGG  
Reverse TTGGAAGGTTCAGGTTGTTTTCT  
IL4 Forward CGGCAACTTTGTCCACGGA  
Reverse TCTGTTACGGTCAACTCGGTG  
S100A8 Forward ATGCCGTCTACAGGGATGAC  
Reverse ACACTCGGTCTCTAGCAATTTCT  
S100A9 Forward GGTCATAGAACACATCATGGAGG 
Reverse GGCCTGGCTTATGGTGGTG  
HNRNPK Forward GCAGGAGGAATTATTGGGGTC  
Reverse TGCACTCTACAACCCTATCGG 
HNRNPD Forward GCGTGGGTTCTGCTTTATTACC  
Reverse TTGCTGATATTGTTCCTTCGACA  
MYC Forward GGCTCCTGGCAAAAGGTCA 
Reverse AGTTGTGCTGATGTGTGGAGA  
PTGS2 Forward CCAGTATAAGTGCGATTGTACCC 
Reverse TCAAAAATTCCGGTGTTGAGCA  
EGR1 Forward GGTCAGTGGCCTAGTGAGC 
Reverse GTGCCGCTGAGTAAATGGGA  
IL17C Forward CCACACTGCTACTCGGCTG 
Reverse CACACGGTATCTCCAGGGTGA  
EGFR Forward AGGCACGAGTAACAAGCTCAC 
Reverse ATGAGGACATAACCAGCCACC  
ACTB Forward CATGTACGTTGCTATCCAGGC  
Reverse CTCCTTAATGTCACGCACGAT  
GAPDH Forward AAGGTGAAGGTCGGAGTCAAC  
Reverse GGGGTCATTGATGGCAACAATA  
RPS18 Forward GCGGCGGAAAATAGCCTTTG 






Immunoprecipitation of hnRNP K-containing RNP complexes (RIP assay) 
 Cells were grown on 15 cm plates until 80-90% confluent. RIP assay was performed 
using RiboCluster Profiler RIP-Assay Kit (MBL Intl, Code RN1001) and hnRNP K pAb (MBL 
Intl, RN019P) according to manufacturer’s protocol, with alterations. 30 ug of hnRNP K Ab or  
IgG control was used per confluent 15 cm plate, and antibodies were preincubated with 30 ul 
of Thermo Scientific Pierce Protein A/G Magnetic beads (Cat no. 88803) overnight. All the 
centrifugations were substituted for separations on a magnetic stand. After cells lysis in 
accordance with the MBL (manufacturer) protocol, equal aliquots of the lysate (input; 5% of 
total lysate;) were taken for quality control by Western blotting and RNA isolation followed by 
qRT-PCR. Quality control samples were also taken after incubating cell lysates (IP; 5% of 
total lysate;) with the immobilized antibody to confirm immunoprecipitation of hnRNP K. For 
qPCR analysis, as input was 5% of the IP, all data were normalized signals from the input 
reaction. 
 
Testing of transfection reagents 
A431 cells grown on 6-well plates were transiently transfected with Lipofectamine3000, 
FugeneHD, Fugene6, GeneJuice, Xfect, Continuum, and TransIT. The following amounts of 
reagents and DNA were used for the transfection: 
 
Reagent (transfection time)  OPTIMEM (ul) Reagent (ul)  DNA (ug) 
1. No transfection control 
2. Lipofectamine 3000 (O/N) 250+250  3.75 (L3000)  2.5 (+ 5ul of 
P3000) 
3. GeneJuice (O/N)  100   4.5   1.5 
4. Continuum (O/N)  250   3.75   1.25 
5. Xfect Clonetech (O/N) 100    7.5   2.5 
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6. TransIT (O/N)  250   7.5   2.5 
7. Fugene6 (O/N)  100   4.5   1.5 
8. FugeneHD (O/N)  100   4.5   1.5 
TPA stimulation and RNA harvest was performed 48 hrs after transfection. 
 
Chemical treatments 
 Cells were serum starved in 0.1% FBS DMEM medium with puromycin for > 12 hours. 
TPA (12-O-Tetradecanoylphorbol-13-Acetate) was used at a 200 nM final concentration and 
treatments were done for 90 minutes prior to processing for RNA isolation. IFNγ was used at 
a 50 ng/mL final concentration for 6 hours. EGF was used at 25 ng/mL, also for 6 hours. 
Actinomycin D was used at 1 µg/mL concentration. Appropriate vehicle controls were used 
for each bioactive chemical tested (DMSO for TPA and Actinomycin D, PBS for IFNγ, 0.1% 
FBS DMEM for EGF). 
 When treated with RSK inhibitors, subconfluent and serum-starved A431 cells were 
first pretreated with an inhibitor (at 2.5 uM concentration) or DMSO vehicle control for 2 hours 
and subsequently treated with TPA for 1.5 hours. 
 
Western blotting 
 Quality control samples from RIP assays were mixed 1:1 with 2X Laemmli sample 
buffer supplemented with 10% β-mercaptoethanol and boiled for 10 minutes. Samples were 
resolved by SDS-PAGE in 10% gels (Bio-Rad Power Pac 1000 source, Bio-Rad Casting 
Stand, Bio-Rad Mini Trans-Blot Cell tank) and transferred to 0.45µm nitrocellulose membrane 
(Bio-Rad) for 100 minutes at 100V. Membranes were then blocked with 5% bovine serum 
albumin (BSA, Sigma) in TBS-T buffer (w/w) for 1 hr at RT followed by an overnight 
incubation with primary antibodies against hnRNP K (3C2, Santa Cruz Biotechnology, 
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1:2000) or K17 (in house rabbit pAb, 1:10000) diluted in 5% BSA in TBS-T at 4°C. Next day, 
membranes were washed 3 times for 5 minutes with TBS-T and then incubated for 1 hr with 
horseradish peroxidase (HRP)-conjugated secondary antibodies (anti-mouse for hnRNP K 
and anti-rabbit for K17) diluted 1:10000 in 5% BSA in TBS-T. Membranes then were washed 
again, before addition of GE Healthcare ECL Western Blotting Substrates. 
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